A Phase 1/2a, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered Alone and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors
Latest Information Update: 25 Apr 2025
At a glance
- Drugs Pembrolizumab (Primary) ; RIVAL-01 (Primary)
- Indications Advanced breast cancer; Cholangiocarcinoma; Colorectal cancer; Malignant melanoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms RAPTOR
- Sponsors Turnstone Biologics
Most Recent Events
- 21 Nov 2023 Status changed from active, no longer recruiting to discontinued.
- 08 Feb 2023 Planned End Date changed from 30 Jul 2025 to 31 Dec 2023.
- 08 Feb 2023 Planned primary completion date changed from 30 Dec 2024 to 30 Jun 2023.